Pharmexa A/S - Minutes of extraordinary general meeting


To OMX Nordic Exchange
and the press


Announcement no. 19/2008


Pharmexa A/S - Minutes of extraordinary general meeting

Minutes of extraordinary general meeting of Pharmexa A/S



The proposals by the Board of Directors to reduce the share capital at a price
of DKK 40 per share by transfer to a special fund that may only be used as
resolved by the general meeting, and to change the face value of the company's
shares as well as the minimum subscription price was adopted. The company's
creditors will be requested to file their proofs of claim against the company
within a period of three months. The capital reduction and the change of face
value of the shares, etc. will only be implemented upon expiry of the
three-month period. 

Hørsholm, 1 July 2008 
Jakob Schmidt 
Chief Executive Officer 

For further information:
Jakob Schmidt, Chief Executive Officer, tel. +45 4516 2525
Claude Mikkelsen, Vice President, Corporate Affairs and Communication, 
tel. +45 4516 2525 or +45 4060 2558 









For the editors: Pharmexa A/S is a development stage company in the field of
active immunotherapy. Pharmexa's proprietary technology platforms are broadly
applicable, allowing the company to address critical targets in cancer and
chronic diseases, as well as serious infectious diseases such as HIV,
influenza, hepatitis and malaria. Collaborative agreements include H. Lundbeck,
Bavarian Nordic and Ichor Medical Systems. With operations in Denmark and USA,
Pharmexa employs approximately 40 employees and is listed on the Copenhagen
Stock Exchange under the trading symbol PHARMX.